ClinicalTrials.gg
Active, not recruitingNCT05755984Updated Oct 7, 2026

3D Printed Breast Models in the Surgical Management of Breast Cancer

An interventional study of 3D printed model in Breast Cancer, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 7, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center — 29 open to participants now, 71 under way, 3 of them phase 3. Breast Neoplasms · M.D. Anderson Cancer Center.

Enrollment
128th of 177
20 · median 40
Started
2024
with 2 others
No phase
61 of 230
10 open now
Primary completion
2028-02
later than 50 of 70 live
Registered
210th of 230
by date

Among the 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center, this one is the 128th largest by enrollment of the 177 interventional ones that give a count, is one of 3 that started in 2024, is one of 61 with no phase, reaches primary completion later than 50 of the 70 other live ones, and was the 210th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

29 of the 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Breast Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

To learn if providing a 3-D printed model of the breast can help breast cancer patients make decisions related to their care. During this study, some study participants will receive the 3-D printed model and some study participants will receive traditional breast imaging scans to learn if the 3-D printed model

Read the detailed description

Primary Objective:

•The objective of this prospective study is to determine the impact of 3D printed breast models, compared to 2D imaging, on breast cancer patients' decisional conflict related to treatment decision-making.

Secondary Objective:

  • To observe if patients will change their initial desired surgical option (mastectomy versus lumpectomy) after viewing the 3D printed models
  • To evaluate the quality of the communication between surgical providers and patients with and without the 3D printed models
  • To assess the surgical outcome including the margin status
  • To evaluate patient satisfaction and well-being post-surgery between the 3D printed model group and the control group as well as mastectomy versus lumpectomy subgroups
  • To assess surgical providers' response to the acceptability and utility of the model
03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older female
  • Patient must have confirmed breast
  • Patient is a candidate for surgical management
  • Patient has a surgeon at MDACC (main campus and/or Houston Area Locations)
  • Patient has a breast MRI for extent of disease assessment at MDACC (main campus and/or Houston Area Locations).
  • Patient is able to speak, read or write English
  • Patient is willing to be randomized to the control or 3D printed breast model groups and is willing to sign the consent form.

Exclusion criteria

Exclusion Criteria:

  • Pregnant and breastfeeding patients
  • Patients who had history of mastectomy, have recurrent on the mastectomy side
  • Patients for whom it is not feasible to create a 3D printed breast model from breast MRI
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Arm 1: 3D printed model

    a 3-D printed model of your breast will be created and discussed with participants during your surgical consultation.

    Diagnostic Test: 3D printed model

  • No intervention
    Arm 2: No 3D printed model

    Participants will have a standard-of-care surgical consultation using traditional breast imaging.

Interventions

  • Diagnostic test3D printed model

    scan

06

What researchers measure

Primary outcomes

  1. Decision Conflict Scale (DCS) score questionnaires

    Score scale ranges: Strongly Agree 1, Agree 2 Neither agree or Agree 3 Strongly Disagree 4

    Time frame: through study completion; an average of 1 year.

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2028, 47 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 47 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2026 → Feb 2028, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2023
First posted
Mar 6, 2023
StartActual
Feb 29, 2024
Primary completionEst.
Feb 28, 2028was Feb 2026
CompletionEst.
Feb 28, 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 28, 2026→Feb 28, 2028
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Primary completion Feb 28, 2026→Feb 28, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05755984
Collaborators
University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Feb 29, 2024
Primary completion
Feb 28, 2028 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Lauren Chang Sen, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion